Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma

Hematol Oncol. 2016 Mar;34(1):49-51. doi: 10.1002/hon.2163. Epub 2014 Sep 22.
No abstract available

Keywords: Hodgkin's lymphoma; allogeneic transplantation; multi-relapsed; pegylated liposomal doxorubicin; response.

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Allografts
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bendamustine Hydrochloride / administration & dosage
  • Brentuximab Vedotin
  • Carmustine / administration & dosage
  • Combined Modality Therapy
  • Cytarabine / administration & dosage
  • Doxorubicin / administration & dosage
  • Doxorubicin / analogs & derivatives*
  • Doxorubicin / therapeutic use
  • Drug Resistance, Neoplasm
  • Etoposide / administration & dosage
  • Hematopoietic Stem Cell Transplantation*
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / radiotherapy
  • Hodgkin Disease / therapy
  • Humans
  • Immunoconjugates / administration & dosage
  • Immunoconjugates / adverse effects
  • Lenalidomide
  • Liposomes
  • Male
  • Melphalan / administration & dosage
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / therapeutic use
  • Recurrence
  • Remission Induction
  • Salvage Therapy*
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives
  • Transplantation, Autologous
  • Young Adult

Substances

  • Antibiotics, Antineoplastic
  • Immunoconjugates
  • Liposomes
  • liposomal doxorubicin
  • Cytarabine
  • Polyethylene Glycols
  • Thalidomide
  • Etoposide
  • Brentuximab Vedotin
  • Doxorubicin
  • Bendamustine Hydrochloride
  • Lenalidomide
  • Melphalan
  • Carmustine

Supplementary concepts

  • BEAM regimen